Azilect and Zelapar are new options on the horizon for Parkinson's

Azilect and Zelapar are new options on the horizon for Parkinson's.

Azilect (rasagiline) is an MAO-B inhibitor similar to selegiline. It works by blocking the breakdown of dopamine.

Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's. It can also be added to levodopa...to prolong its effects in patients with more advanced Parkinson's.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote